Начало・Списък с акции・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Затворен

СекторЗдравеопазване

19.11 1.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.8

Максимум

19.34

Ключови измерители
By Trading Economics
Приходи	-24M -54M
Продажби	-2.5M 305M
EPS	-0.15
Марж на печалбата	-17.851
Служители	3,100
EBITDA	-24M -32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+175.38% upside

Дивиденти
By Acuity
Следващи печалби	11.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1B 3.7B
Предишно отваряне	17.95
Предишно затваряне	19.11

Настроения в новините

By Acuity

100%

320 / 340 Класиране в Healthcare

Legend Biotech Corp ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 22:01 ч. UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31.07.2026 г., 23:56 ч. UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30.07.2026 г., 22:41 ч. UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29.07.2026 г., 19:27 ч. UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28.07.2026 г., 22:56 ч. UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27.07.2026 г., 23:16 ч. UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24.07.2026 г., 19:16 ч. UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22.07.2026 г., 18:31 ч. UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21.07.2026 г., 16:46 ч. UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20.07.2026 г., 19:01 ч. UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Сравнение с други в отрасъла

Ценова промяна

Legend Biotech Corp ADR Прогноза

Ценова цел

By TipRanks

175.38% нагоре

12-месечна прогноза

Среден 52.35 USD 175.38%

Висок 80 USD

Нисък 28 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Legend Biotech Corp ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Legend Biotech Corp ADR през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.